| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-07 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.29 | 5e-05 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.0003 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.0004 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.17 | 0.0008 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0008 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0009 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |